{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:57:46Z","timestamp":1788872266617,"version":"build-2803163510"},"reference-count":37,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of ubrogepant for the acute treatment of perimenstrual migraine (pmM) attacks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ubrogepant is an oral calcitonin gene\u2010related peptide receptor antagonist approved for the acute treatment of migraine in adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>After completing one of two phase 3 trials, participants could enroll in a phase 3, 52\u2010week, open\u2010label, long\u2010term safety extension trial and were re\u2010randomized 1:1:1 to usual care, ubrogepant 50\u2009mg, or ubrogepant 100\u2009mg. This post hoc analysis evaluated the efficacy of ubrogepant in a subset of women who treated \u22651 pmM or non\u2010pmM attack with ubrogepant. A pmM attack started on or between 2\u2009days before and the first 3\u2009days of menstrual bleeding. Mean (standard deviation [SD]) percentages of ubrogepant\u2010treated attacks achieving 2\u2010h pain freedom and pain relief were reported, with outcomes weighted equally by participant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 734 women in the modified intent\u2010to\u2010treat population, 354 reported \u22651 menstrual cycle start date and a ubrogepant\u2010treated headache day in the same month. A qualifying pmM and non\u2010pmM attack was reported by 278 and 716 women, respectively. Pain freedom at 2\u2009h was achieved in a mean (SD) of 28.7% (37.4) of pmM attacks and 22.1% (26.9) of non\u2010pmM attacks treated with ubrogepant 50\u2009mg (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.054) and 29.7% (35.2) versus 25.3% (26.3) of attacks treated with ubrogepant 100\u2009mg (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.757). No difference was found in the mean percentage of ubrogepant\u2010treated pmM and non\u2010pmM attacks that achieved 2\u2010h pain relief with ubrogepant 50\u2009mg (64.8% [39.9] vs. 65.2% [32.4];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.683) and with 100\u2009mg (67.1% [37.4] vs. 68.4% [30.2];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.273). Treatment\u2010related treatment\u2010emergent adverse events were reported by 8.8% (12\/137) and 12.8% (18\/141) in the ubrogepant 50 and 100\u2009mg pmM subgroups, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ubrogepant demonstrated similar efficacy for the treatment of pmM and non\u2010pmM attacks. No new safety signals were identified.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.14619","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T05:43:43Z","timestamp":1693547023000},"page":"1135-1144","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety and efficacy of ubrogepant for the acute treatment of perimenstrual migraine attacks: A post hoc analysis"],"prefix":"10.1111","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4116-9828","authenticated-orcid":false,"given":"E. Anne","family":"MacGregor","sequence":"first","affiliation":[{"name":"Centre for Neuroscience, Surgery and Trauma, Blizard Institute of Cell and Molecular Science Barts and the London School of Medicine and Dentistry  London UK"},{"name":"Centre for Reproductive Medicine, St. Bartholomew's Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6353-2846","authenticated-orcid":false,"given":"Susan","family":"Hutchinson","sequence":"additional","affiliation":[{"name":"Orange County Migraine and Headache Center  Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxin","family":"Lai","sequence":"additional","affiliation":[{"name":"AbbVie  Madison New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Dabruzzo","sequence":"additional","affiliation":[{"name":"AbbVie  Madison New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Yun","family":"Yu","sequence":"additional","affiliation":[{"name":"AbbVie  Madison New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M.","family":"Trugman","sequence":"additional","affiliation":[{"name":"AbbVie  Madison New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Ailani","sequence":"additional","affiliation":[{"name":"Department of Neurology MedStar Georgetown University Hospital  DC Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,9]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13613"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2019.06.001"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252808.97649.21"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12150"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102409355601"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756285609335537"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2007.01279.x"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2019-002332"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2020.07.005"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-015-0503-y"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40695-020-00059-8"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30482-8"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012723"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10194-012-0424-y"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12198"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13665"},{"key":"e_1_2_13_19_1","unstructured":"Ubrelvy [package insert].AbbVie Inc.;2023."},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.16711"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813049"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13682"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)30293-9"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417739584"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002798"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-017-0816-0"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/2053369117731172"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2004.00741.x"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024211000311"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2007.01053.x"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2005.00981.x"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10786"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102415584308"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01167-6"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102415575723"},{"key":"e_1_2_13_36_1","first-page":"1","article-title":"Oral contraceptive use and its association with symptomatology in migraine patients","volume":"2","author":"Peng KP","year":"2019","journal-title":"Cephalalgia Rep"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/1129-2377-14-66"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1783\/147118902101195974"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14619","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:23:57Z","timestamp":1762079037000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1111\/head.14619"],"URL":"https:\/\/doi.org\/10.1111\/head.14619","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"2022-11-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}